Pylarify patents expiration

PYLARIFY's oppositions filed in EPO
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487129 PROGENICS PHARMS INC Heterodimers of glutamic acid
Nov, 2027

(4 years from now)

US9861713 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Jul, 2029

(5 years from now)

US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(7 years from now)

US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(13 years from now)

Pylarify is owned by Progenics Pharms Inc.

Pylarify contains Piflufolastat F-18.

Pylarify has a total of 4 drug patents out of which 0 drug patents have expired.

Pylarify was authorised for market use on 26 May, 2021.

Pylarify is available in solution;intravenous dosage forms.

Pylarify can be used as method of positron emission tomography (pet) in men with prostate cancer.

Drug patent challenges can be filed against Pylarify from 2025-05-26.

The generics of Pylarify are possible to be released after 09 June, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 2025-05-26

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer


More Information on Dosage

PYLARIFY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic